Dieses Bild zeigt Jörn Lausen

Jörn Lausen

Herr Prof. Dr. rer. nat.

Direktor, Institutsleiter
Institut für Biomedizinische Genetik
Abt. Eukaryoten Genetik, Dept. Eukaryote Genetics

Kontakt

+49 711 685 66971
 +49 711 685 66973

Allmandring 31
70569 Stuttgart
Deutschland
Raum: 1.203-1.205

  1. Schneider, L; Herkt ,S.; Wang L, Feld, C.: Wesely, J.; Kuvardina, ON.; Meyer, A.; Oellerich, T.; Häupl, B.; Seifried, E.; Bonig, H.; Lausen, J.:
    PRMT6 activates cyclin D1 expression in conjunction with the transcription factor LEF1.
    Oncogenesis. 2021 May 17;10(5):42. doi: 10.1038/s41389-021-00332-z.PMID:34001852 

  2. Meyer, A.; Herkt, S.; Kunze-Schumacher, H.; Kohrs, N.; Ringleb, J.; Schneider, L.; Kuvardina, ON.; Oellerich, T.; Häupl, B.; Krueger, A.; Seifried, E.; Bonig, H.; Lausen, J.: The transcription factor TAL1 and miR-17-92 create a regulatory loop in hematopoiesis.
    Sci Rep. 2020 Dec 8;10(1):21438. doi: 10.1038/s41598-020-78629-z. PMID:33293632 

  3. Roth, H; Schneider, L.; Eberle, R.; Lausen, J.; Modlich, U.; Blümel, J.; Baylis SA.:Zika virus infection studies with CD34+hematopoietic and megakaryocyte-erythroid progenitors, red blood cells and platelets.
    Transfusion. 2020 Mar;60(3):561-574. doi: 10.1111/trf.15692. Epub 2020 Feb 22. PMID: 32086956

  4. Godavarthy, PS.; Kuma, R.; Herkt, SC.; Pereira, RS.; Hayduk, N; Weissenberger, ES.; Aggoune, D.; Manavski, Y.; Lucas, T.; Pan, KT; Voutsinas, JM.; Wu, Q.; Müller, MC.; Saussele, S.; Oellerich, T.; Oehler, VG.; Lausen, J. Krause, DS.: The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin - SCL/TAL1 - CD44 axis.
    Haematologica. 2020 Jan;105(1):136-147. doi:10.3324/haematol.2018.212365. Epub 2019 Apr 24. PMID: 31018977
  1. Windisch, R.; Pirschtat, N.; Kellner, C., Chen-Wichmann, L.; Lausen, J.; Humpe, A.; Krause, DS.; Wichmann, C.:
    Oncogenic Deregulation of Cell Adhesion Molecules in Leukemia.
    Cancers (Basel). 2019 Mar 5;11(3). pii: E311. doi: 10.3390/cancers11030311. Review. PMID:30841639

  2. Chen-Wichmann, L.; Shvartsman, M.; Preiss, C.; Hockings, C.; Windisch, R, Redondo Monte E, Leubolt G, Spiekermann K, Lausen J, Brendel C, Grez M.; Greif, P.A.; Wichmann, C.:
    Compatibility of RUNX1/ETO fusion protein modules driving CD34+ human progenitor cell expansion.
    Oncogene. 2019 Jan;38(2):261-272.
  1. Steiner, M.; Schneider, L.; Yillah, J.; Gerlach, K.; Kuvardina, O.N.; Meyer, A.; Maring, A.; Bonig, H.; Seifried, E.; Zörnig, M.; Lausen, J. FUSE binding protein 1 (FUBP1) expression is upregulated by T-cell acute lymphocytic leukemia protein 1 (TAL1) and required for efficient erythroid differentiation. PLoS One. 2019 Jan 17;14(1).

  2. Kramer, J.; Désor, V.; Brunst, S.; Wittmann, S.K.; Lausen, J.; Heering, J.; Proschak, A. and Proschak, E.: A coupled fluorescence-based assay for the detection of protein arginine N-methyltransferase 6 (PRMT6) enzymatic activity.
    Anal Biochem. 547: 7-13. 2018 Apr 15
  1. Herkt SC.; Kuvardina, O.N.; Herglotz, J.; Schneider, L.; Meyer, A.; Pommerenke, C.; Salinas-Riester, G.; Seifried, E.; Bonig, H.; Lausen, J.: Protein arginine methyltransferase 6 controls erythroid gene expression and differentiation of human CD34+ progenitor cells.
    Haematologica. 103(1): 18-29. 2018 Jan

  2. Schanda, J.; Lee, C.W.; Wohlan, K.; Müller-Kuller, U.; Kunkel, H.; Quagliano-Lo Coco, I.; Stein, S.; Metz, A.; Koch, J.; Lausen, J.; Platzbecker, U.; Medyouf, H.; Gohlke, H.; Heuser, M.; Eder, M.; Grez, M.; Scherr, M.; Wichmann, C.:Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization.
    Haematologica, 102(5): e170-e174. 2017 May
  1. Kuvardina, O.N.; Herkt, S.; Meyer, A.; Schneider, L.; Yillah, J.; Kohrs, N.; Bonig, H.; Seifried, E.; Müller-Tidow, C.; Lausen, J.: Hematopoietic transcription factors and differential cofactor binding regulate PRKACB isoform expression.
    Oncotarget. 8(42): 71685-71698. 2017 Apr 24.
  1. Kohrs, N.; Kolodziej, S.; Kuvardina, O.N.; Herglotz, J.; Yillah, J.; Herkt, S.; Piechatzek, A.; Salinas-Riester, G.; Lingner, T.; Wichmann, C.; Bonig, H.; Seifried, E.; Platzbecker, U.; Medyouf, H.; Grez, M. and Lausen, J.: MiR144/451 expression is repressed by RUNX1 during megakaryopoiesis and disturbed by RUNX1/ETO.
    PLoS Genet.,12(3): e1005946. 2016 Mar 18
  1. Kuvardina, O.N.; Herglotz, J.; Kolodziej, S.; Kohrs, N.; Wojcik, B.; Oellerich, T.; Corso, J.; Behrens, K.; Kumar, A.; Hussong, H.; Urlaub, H; Koch, J.; Serve, H.; Bonig, H.; Stocking, C.; Rieger, M.; Lausen, J.:
    RUNX1 represses the erythroid gene expression program during megakaryocytic differentiation.
    Blood, 125(23): 3570-9. 2015 Apr 24.
  1. Ponnusamy, K.; Kohrs, N.; Ptasinska, A.; Assi, S.; Herold, T.; Weigert, O.; Hiddemann, W; Lausen, J.; Bonifer, C.; Henschler, R.; Wichmann, C.: RUNX1/ETO blocks selection binding via transcriptional repression of PSGL-1. Oncogenesis, 4:e146. 2015 April 13.

  2. Müller-Kuller, U.; Ackermann M.; Kolodziej, S.; Brendel, C.; Fritsch, J; Lachmann, N.; Kunkel, H.; Lausen, J.; Schambach, A.; Moritz, T.; Grez, M.:
    A minimal ubiquitous chromatin opening element (UCOE) effectively prevents silencing of juxtaposed heterologous promoters by epigenetic remodeling in multipotent and pluripotent stem cells.
    Nucleic Acids Research, 18;43(3):1577-92. 2015.
  1. Ponnusamy, K.; Chen-Wichmann, L.; Kuvardina, O.N.; Lausen, J.; Henschler, R.; Wichmann, C.: The truncated Runx1/Eto activates Vla-4-dependent adhesion and migration of hematopoietic progenitor cells.
    Haematologica, 99(12): e253-6. 2014 Dec.
  1. Kolodziej, S.; Kuvardina, O.N.; Oellerich T.; Herglotz, J.; Backert, I.; Kohrs, N.; Buscató, E.; Wittmann, S.K.; Salinas-Riester, G.; Bonig, H.; Karas, M.; Serve, H.; Proschak, E.; Lausen, J.: 
    PADI4 acts as a coactivator of Tal1 by counteracting repressive histone arginine methylation.
    Nature Communications, 5: 3995. 2014 May 29.

  2. Ng, K.P.; Hu, Z.; Ebrahem, Q.; Negrotto, S.; Lausen, J.; Saunthararajah, Y.: Runx1 deficiency permits granulocyte lineage commitment but impairs subsequent maturation.
    Oncogenesis, 2, e78. 2013 Nov 4. W3.
  1. Courtial, N.; Mücke, C.; Herkt, S.; Kolodziej, S.; Hussong H.; Lausen, J.:
    The T-cell oncogene Tal2 is a target of PU.1 and upregulated during osteoclastogenesis.
    PLoS ONE, 8(9): e76637. 2013.

  2. Herglotz, J.; Kuvardina, O.N.; Kolodziej, S.; Kumar, A.; Hussong, H.; Grez, M.; Lausen, J.: Histone arginine methylation keeps RUNX1 target genes in an intermediate state.
    Oncogene, 32(20): 2565-75. 2013 May 16.

  3. Courtial, N.; Smink, J.J.; Kuvardina, O.N.; Leutz, A.; Göthert, J.R.; , J.: Tal1 regulates osteoclast differentiation through suppression of the master regulator of cell fusion DC-STAMP.
    FASEB Journal, 26(2): 523-532. 2012 Feb

  4. Bangert, A.; Cristofanon, S.; Eckhardt, I.; Abhari, B.A.; Kolodziej, S.; Häcker, S.; Vellanki, S.H.K.; Lausen, J.; Debatin, K.M.; Fulda, S.: Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP.
    Oncogene, 31(44): 4677-88. 2012 Nov 1.
  1. Wichmann, C.; Becker, Y.; Chen-Wichmann, L.; Vogel, V.; Vojtkova, A.; Herglotz, J.; Moore, S.; Koch, J.; Lausen, J.; Mäntele, W.; Gohlke, H.; Grez, M.: Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity.
    Blood, 116(4): 603-13. 2010 Jul 29.

  2. Lausen, J*.; Pless, O.; Leonard, F.; Kuvardina, O.N.; Koch, B.; Leutz, A.: Targets of the Tal1 transcription factor in erythrocytes: E2 ubiquitin conjugase regulation by Tal1.
    Chem., 285(8): 5338-46. 2010 Feb.
  1. Pless, O.; Kowenz-Leutz, E.; Knoblich, M.; Lausen, J.; Beyermann, M.; Walsh, M.J.; Leutz, A.: G9a-mediated lysine methylation alters the function of CCAAT/enhancer-binding protein-beta.
    Chem., 283(39): 26357-63, 2008 Sep 26.
  1. Wei, Y.; Liu, S.*; Lausen, J*.; Cho, S.; Biris, N.; Kobayashi, N.; Wei, Y.; Yokoyama, S.; Werner, M.H.: A TAF4-homology domain from the co-repressor Eight Twenty-one (ETO) is a docking platform for positive and negative regulators of transcription. 2007.
    Struct. Mol. Biol., 14(7): 653-661, 2007 Jul. *Equal contr.
  1. Erdmann, S.; Senkel, S.; Arndt, T.; Lucas, B.; Lausen, J.; Klein-Hitpass, L.; Ryffel, G.U.; Thomas, H.: The tissue specific transcription factor HNF4a inhi-bits cell proliferation and induces apoptosis in the pancreatic INS-1 b-cell line. Chem., 388(1): 91-106. 2007 Jan.
  1. Lausen, J.; Liu, S.; Fliegauf, M.; Lubbert, M.; Werner, M.H.:
    ELA2 is regu-lated by hematopoietic transcription factors, but not repressed by AML1-ETO.
    Oncogene, 25(9): 1349-57. 2006 Mar 2.
  1. Lucas, B.; Grigo, K.; Erdmann, S.; Lausen, J.; Klein-Hitpass, L.; Ryffel, G.U.: HNF4alpha reduces proliferation of kidney cells and affects genes deregulated in renal cell carcinoma.
    Oncogene, 24(42): 6418-31. 2005 Sept 22.
  1. Lausen, J.; Cho, S.; Liu, S.; Werner, M.H.: The nuclear receptor co-repressor (N-CoR) utilizes repression domains I and III for interaction and co-repression with ETO. J.
    Chem., 279 (47): 49281-8. 2004 Nov 19.
  1. Thomas, H.; Badenberg, B.; Bulman, B.; Lemm, I.; Lausen J.; Kind, L.; Roosen, S.; Ellard, S.; Hattersley, A.; Ryffel, G.U.:
    Evidence for haploinsufficiency of the human HNF1a gene by functional characterization of MODY3-associated mutations.
    Chem., 383: 1691-1700, 2002 Nov.
  1. Lausen, J.; Thomas, H.; Lemm, I.; Bulman, M.; Borgschulze, M.; Lingott, A.; Hattersley, A.T.; Ryffel, G.U.:
    Naturally occurring mutations in the human HNF4a gene impair the function of the transcription factor to a varying degree.
    Nucleic Acids Research, 28: 430-437. 2000 Jan 15.
  1. Puzio, P.S.; Lausen, J.; Heinen, P.; Grundler, F.M.W.:
    Promoter analysis of the nematode responsive pyk 20 gene from arabidopsis thaliana.
    Plant Science, 157: 245-255. 2000 Aug 22.
  1. Puzio, P.S.; Lausen, J.; Almeida-Engler, J.; Cai, D.; Gheysen, G.; Grundler, F.M.W.: Isolation of a gene from arabidopsis thaliana related to nematode feeding structures.
    Gene, 239: 163-172, 1999 Oct.18.

 

2001    Ph.D.-thesis, Dissertation

Title: “Einfluss diabetes-assoziierter Mutationen im Transkriptionsfaktor HNF4a“

 

Review Artikel

  1. Windisch, R.; Pirschtat, N; Kellner, C.; Chen-Wichmann, L.; Lausen, J.; Humpe, A.; Krause, DS.; Wichmann, C.:
    Oncogenic Deregulation of Cell Adhesion Molecules in Leukemia.
    Cancers (Basel). 2019 Mar 5;11(3).
  1. Lausen, J.:Contributions of the Histone Arginine Methyltransferase PRMT6 to the Epigenetic Function of RUNX1.
    Rev. Eukaryot Gene Expr., 23(3):265-74. 2013.
  1. Wichmann, C.; Grez, M.; Lausen, J.:
    Molecular Targeting of Aberrant Transcription Factors in Leukemia: Strategies for RUNX1/ETO.
    Current Drug Targets, 11(9): 1181-91. 2010.

 

 

Prof. Dr. rer. nat. habil Jörn Lausen, Diplom-Biologe

CV

01.04.2019                 W3 Professor für Eukaryotengenetik, Universität Stuttgart

2016-2019                  Forschungsgruppenleiter / Projektleiter
                                  DRK-Blutspendedienst Baden-Württemberg/Hessen,
                                  Institut für Transfusionsmedizin und Imunhämatologie der
                                  Goethe Universität Frankfurt                 

10.07.2017                  Habilitation

2008-2016                  Unabhängiger Nachwuchsgruppenleiter / Projektleiter

                                  Institut für Tumorbiologie und experimentelle Therapie, 
                                  Georg-Speyer-Haus, Frankfurt

2005-2008                 Senior-Postdoktorand                   

                                   Max-Delbrück-Center für Molekulare Medizin, Berlin,
                                   Abteilung Zelldifferenzierung und Tumorentstehung,
                                   Prof. Dr. A. Leutz

2001-2005                  Postdoktorand
                                  Rockefeller Universität, New York, USA
                                  Abteilung für molekulare Biophysik, Prof. Dr. M. Werner

2002-2003                 Forschungsstipendium
                                  (Deutsche Forschungsgemeinschaft)

1998-2001                  Doktorarbeit
                                   Universität Essen, Abteilung für Zellbiologie, Prof. Dr. G. Ryffel

2001                           Promotion mit Summa cum laude

1992-1998                  Studium der Biologie
                                  Christian Albrechts Universität, Kiel

1998                           Diplomarbeit
                                   Christian Albrechts Universität, Kiel
                                   Institut für Phytopathologie, Prof. Dr. F. Grundler

1994                           Vordiplom

1998                           Diplom mit sehr gut

Zum Seitenanfang